MEDP · Nasdaq · Healthcare · Diagnostics and Research
$654.00-0.4%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed October 22, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
Medpace Holdings, Inc.’s own guidance, from its results release of October 21, 2026. It is the company’s statement of what it expects, not a forecast of ours.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $716M | $659.9M | +8.50% |
| Profit | $137.5M | $111.1M | +23.69% |
| Profit per share | $4.84 | $3.86 | +25.39% |
| Free Cash Flow | $196.4M | $235.5M | -16.59% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Medpace Holdings, Inc. has no earnings call transcript available.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined 2 operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 6,600 people across 46 countries as of September 30, 2026.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Medpace Holdings, Inc.’s Item 2.02 8-K filed October 21, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.